163 related articles for article (PubMed ID: 17202112)
1. Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia.
Kitareewan S; Roebuck BD; Demidenko E; Sloboda RD; Dmitrovsky E
J Natl Cancer Inst; 2007 Jan; 99(1):41-52. PubMed ID: 17202112
[TBL] [Abstract][Full Text] [Related]
2. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells.
Müller S; Miller WH; Dejean A
Blood; 1998 Dec; 92(11):4308-16. PubMed ID: 9834237
[TBL] [Abstract][Full Text] [Related]
3. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
4. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites.
Idres N; Benoît G; Flexor MA; Lanotte M; Chabot GG
Cancer Res; 2001 Jan; 61(2):700-5. PubMed ID: 11212271
[TBL] [Abstract][Full Text] [Related]
5. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
[TBL] [Abstract][Full Text] [Related]
6. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
[TBL] [Abstract][Full Text] [Related]
7. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
[TBL] [Abstract][Full Text] [Related]
9. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia.
Riccioni R; Saulle E; Militi S; Sposi NM; Gualtiero M; Mauro N; Mancini M; Diverio D; Lo Coco F; Peschle C; Testa U
Leukemia; 2003 Jan; 17(1):98-113. PubMed ID: 12529666
[TBL] [Abstract][Full Text] [Related]
10. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia.
Zhu J; Koken MH; Quignon F; Chelbi-Alix MK; Degos L; Wang ZY; Chen Z; de Thé H
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3978-83. PubMed ID: 9108090
[TBL] [Abstract][Full Text] [Related]
11. The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells.
Jing Y; Xia L; Lu M; Waxman S
Oncogene; 2003 Jun; 22(26):4083-91. PubMed ID: 12821942
[TBL] [Abstract][Full Text] [Related]
12. Berbamine selectively induces apoptosis of human acute promyelocytic leukemia cells via survivin-mediated pathway.
Zhao XY; He ZW; Wu D; Xu RZ
Chin Med J (Engl); 2007 May; 120(9):802-6. PubMed ID: 17531122
[TBL] [Abstract][Full Text] [Related]
13. Effects of arsenic on modification of promyelocytic leukemia (PML): PML responds to low levels of arsenite.
Hirano S; Watanabe T; Kobayashi Y
Toxicol Appl Pharmacol; 2013 Dec; 273(3):590-9. PubMed ID: 24135626
[TBL] [Abstract][Full Text] [Related]
14. Chloroquine aggravates the arsenic trioxide (As2O3)-induced apoptosis of acute promyelocytic leukemia NB4 cells via inhibiting lysosomal degradation in vitro.
Liu DM; Zhang XD; Yang L
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6412-6421. PubMed ID: 30338810
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein.
Ng AP; Nin DS; Fong JH; Venkataraman D; Chen CS; Khan M
Mol Cancer Ther; 2007 Aug; 6(8):2240-8. PubMed ID: 17699721
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
17. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells.
Nason-Burchenal K; Takle G; Pace U; Flynn S; Allopenna J; Martin P; George ST; Goldberg AR; Dmitrovsky E
Oncogene; 1998 Oct; 17(14):1759-68. PubMed ID: 9778041
[TBL] [Abstract][Full Text] [Related]
19. Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance.
Fanelli M; Minucci S; Gelmetti V; Nervi C; Gambacorti-Passerini C; Pelicci PG
Blood; 1999 Mar; 93(5):1477-81. PubMed ID: 10029573
[TBL] [Abstract][Full Text] [Related]
20. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
